Use of BMMFI Rep protein as biomarker for colorectal cancer

Patent metadata

Field	Value
Publication number	US-12282020-B2
Application number	US-202016939154-A
Country	US
Kind code	B2
Filing date	Jul 27, 2020
Priority date	Jan 30, 2018
Publication date	Apr 22, 2025
Grant date	Apr 22, 2025

Abstract

The present invention relates to the use of BMW Rep-protein as a biomarker for colon cancer.

First claim

What is claimed is:

1. A method for providing a diagnosis or predisposition for colorectal cancer (CRC) in a subject, comprising:
obtaining a sample from a subject;
detecting whether a Bovine Meat and Milk Factor Group 1 (BMMF1) Rep Protein is present in the sample by contacting the sample with one or more antibodies selected from the group consisting of Ab 1-5 (DSM ACC3327), Ab 5-2 (DSM ACC3328) and Ab 3-6 (DSM ACC3329) and detecting binding between BMMF1 and said one or more antibodies; and
providing a diagnosis or predisposition for CRC to the subject when the presence of BMMF1 in the sample is detected.

2. The method of claim 1 , wherein the sample from the subject is selected from the group consisting of a cancerous colon tissue, peripheral tissue surrounding the cancerous colon tissue and benign colon polyps.

3. The method of claim 1 , wherein additionally CD68 positive cells are detected in the sample by an anti-CD68 antibody.

4. A method for providing a prognostic score on a CRC patient's survival time, comprising:
a) obtaining a sample from peritumoral regions of CRC patients;
b) contacting the sample with one or more antibodies selected from the group consisting of Ab 1-5 (DSM ACC3327), Ab 5-2 (DSM ACC3328) and Ab 3-6 (DSM ACC3329),
c) staining the sample to visualize binding between Rep protein and the one or more antibodies;
d) detecting Rep protein in the stained sample by observing the visualized binding;
e) quantifying the detected Rep protein by:
i) determining for each antibody the percentage of stained cells, and
ii) measuring the staining intensity;

f) calculating an immunohistological score based on the quantified Rep protein; and
g) correlating the calculated immunohistological score to a CRC-specific patient's survival time.

Assignees

• Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Inventors

• Bund Timo
• Zur Hausen Harald
• De Villiers-Zur Hausen Ethel-Michele
• Tessmer Claudia
• Heikenwalder Mathias
• Weber Achim
• Burk-Körner Amelie

Classifications

• G01N33/57535 Primary

  of the large intestine, e.g. colon, rectum or anus · CPC title

• G01N2333/70503

  Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3 · CPC title

• G01N33/577

  involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)} · CPC title

• G01N2333/914

  Hydrolases (3) · CPC title

• G01N33/57419 Primary

  Physics · mapped topic